

Tuesday, March 31, 2026

**Published!** 

[An interactive resource mapping the proteome and reactive cysteine landscape across the NCI-60 reveals cell and tissue-specific profiles](#)

Montaño JL, Tejus VR, Xu V, Condon AC, Ecker AK, Langen A, Leung KK, Zaro BW. Cell Chem Biol.

[Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models](#)

Lizzadro L, Li J, Taha TY, Degotte G, Detomasi TC, Zapatero-Belinchon FJ, Hantz ER, Huang S, Matsui Y, Henderson WR, McCann JT, Montano M, Rosecrans J, Torres Pomares DF, McGovern BL, Diaz-Tapia R, Benjamin J, Gordon ME, Suazo ID, Settineri NS, Diallo A, Krogan NJ, Shoichet BK, Verba KA, Albrecht R, García-Sastre A, White KM, Ott M, Craik CS, Renslo AR. J Med Chem.

[Revealing a coherent cell-state landscape across single-cell datasets with CONCORD](#)

Zhu Q, Jiang Z, Zuckerman B, Weinberger L, Thomson M, Gartner ZJ. Nat Biotechnol.

[Structural energetics of cold sensitivity.](#)

Choi KY, L X, Cheng Y, Julius D. Nature

**Awards** 

Aashish Manglik

Clarivate's Highly Cited Researchers 2025

Aashish Manglik

Vilcek Prize for Creative Promise

Brian Shoichet

Clarivate's Highly Cited Researchers 2025

Balyn Zaro

Bowes Biomedical Investigator Award

## Winter 2026 Graduates

Kaan Kumru

Extracellular targeted protein degradation  
expanded by a cytokine receptor–targeting  
chimera toolbox

## CCB Campus Visits **NEW**

13 prospective students visited UCSF between 3/15 - 3/17. Thank you to all the faculty and students that volunteered their time to meet and speak with them!

## CBBA Day 2026 at UCSF

UCSF will host CBBA Day on Saturday, May 2 at UCSF Mission Bay Genentech Hall. Please join us for this exciting day of scientific exchange and community building.



## ALUMNI PROFILE

### Nicholas T. Hertz, PhD

#### Montara Therapeutics

Nicholas T. Hertz, Ph.D., is the Founder and CEO of Montara Therapeutics, a seed-stage biotechnology company developing therapies for brain diseases by leveraging its proprietary BrainOnly™ platform. This CNS-targeting technology, developed in the Shokat Lab at UCSF, enhances drug safety and efficacy and enables modulation of previously undruggable targets. Dr. Hertz earned a B.S. in Biochemistry from UCLA (magna cum laude) and completed his Ph.D. in Chemistry and Chemical Biology at UCSF, where he discovered the first class of PINK1-activating molecules and co-founded Mitokinin Inc. After postdoctoral work in neuroscience at Stanford, he served as CSO at Mitokinin, leading both scientific and capital strategy efforts. Under his leadership, the company advanced novel PINK1 activators toward clinical development and was acquired by AbbVie in 2023 in a deal valued at up to \$655 million. At Montara, Dr. Hertz continues to prioritize rigorous, mechanism-driven science alongside a disciplined and capital-efficient approach to company building. His work has resulted in over 20 publications in journals such as Cell, Neuron, and Nature, and more than 20 issued or pending patents. A father of three and avid surfer, Dr. Hertz finds perspective and creativity in both nature and science.

## Resources

### [Student Food Market](#)

Thursdays 3:30 to 5:30 p.m.

Mission Hall 1300

(adjacent to the lobby)

### [Student Health Services](#)

### [Job Opportunities](#)

## Have news?

Reach out to us!

**Arezou Razavi** (she/her)

[arezou.razavi@ucsf.edu](mailto:arezou.razavi@ucsf.edu)

415-476-1914

Genentech Hall MC2280

600 16th St Rm 522

San Francisco CA 94143